Recent Updates
Recently added Catalysts

Relapsed or Refractory Non-Hodgkin's Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$601Muniverse median $1.20B
Allocated capital$601M$601M competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank192/299crowding rank 202

Relapsed or Refractory Non-Hodgkin's Lymphoma is uncontested. Arvinas (ARVN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with ARV-393 in phase 1.

There is no public comparable to price it against, and ARVN runs clinical programmes in this indication and nothing else, so its $601M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$601M of allocated capital sits in Relapsed or Refractory Non-Hodgkin's Lymphoma, ranking it 192nd of 299 indications by the money committed to it.

Companies developing drugs for Relapsed or Refractory Non-Hodgkin's Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ARVNArvinasARV-393Phase 12$601MYes1 31 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Relapsed or Refractory Non-Hodgkin's Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Relapsed or Refractory Non-Hodgkin's Lymphoma has one competitor and a median of $601M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Castration-Resistant Metastatic Prostate Cancer1 company · $613M · median $1.2BUncontestedMyelodysplastic Syndromes2 companies · $572M · median $1.5BConcentrated betAdvanced Cutaneous Melanoma1 company · $634M · median $1.3BUncontestedMalignant Melanoma1 company · $657M · median $3.9BUncontestedUnresectable Melanoma1 company · $657M · median $3.9BUncontestedMetastatic Hepatocellular Carcinoma1 company · $495M · median $1.5BUncontestedHER2 Expressing/Amplified Solid Tumors1 company · $484M · median $1.9BUncontestedHormone-refractory Prostate Adenocarcinoma1 company · $484M · median $1.9BUncontested

Relapsed or Refractory Non-Hodgkin's Lymphoma pipeline questions

Which biotech companies are developing drugs for Relapsed or Refractory Non-Hodgkin's Lymphoma?

Arvinas (ARVN, ARV-393, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Relapsed or Refractory Non-Hodgkin's Lymphoma.

How advanced is the Relapsed or Refractory Non-Hodgkin's Lymphoma pipeline?

Of the 1 clinical-stage programme in Relapsed or Refractory Non-Hodgkin's Lymphoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Relapsed or Refractory Non-Hodgkin's Lymphoma?

No. ARVN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Relapsed or Refractory Non-Hodgkin's Lymphoma, which is why the indication is classified as uncontested.

When is the next Relapsed or Refractory Non-Hodgkin's Lymphoma catalyst?

The next dated catalyst in Relapsed or Refractory Non-Hodgkin's Lymphoma is ARVN on 31 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map